Biogen and Abbvie asserted voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis. Taking into account the limited number of patients who are being treated, beneefit/risk profile of ZINBRYTA will not be possible.
Alfred Sandrock, M.D., Ph.D., executive vice president and chief medical officer at Biogen said “Biogen and AbbVie continue to prioritize patient safety and the care of multiple sclerosis patients worldwide.”
ZINBRYTA (daclizumab) is currently available in the EU, U.S., Switzerland, Canada and Australia. ZINBRYTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS). Because of its risks, ZINBRYTA is generally used in people who have tried two or more MS medicines that have not worked well enough. It is not known if ZINBRYTA is safe and effective for use in children under 18 years of age.